| Literature DB >> 33123599 |
Raffaele Galiero1, Pia Clara Pafundi1, Riccardo Nevola1, Luca Rinaldi1, Carlo Acierno1, Alfredo Caturano1, Teresa Salvatore2, Luigi Elio Adinolfi1, Ciro Costagliola3, Ferdinando Carlo Sasso1.
Abstract
Recently, telemedicine has become remarkably important, due to increased deployment and development of digital technologies. National and international guidelines should consider its inclusion in their updates. During the COVID-19 pandemic, mandatory social distancing and the lack of effective treatments has made telemedicine the safest interactive system between patients, both infected and uninfected, and clinicians. A few potential evidence-based scenarios for the application of telemedicine have been hypothesized. In particular, its use in diabetes and complication monitoring has been remarkably increasing, due to the high risk of poor prognosis. New evidence and technological improvements in telemedicine application in diabetic retinopathy (DR) have demonstrated efficacy and usefulness in screening. Moreover, despite an initial increase for devices and training costs, teleophthalmology demonstrated a good cost-to-efficacy ratio; however, no national screening program has yet focused on DR prevention and diagnosis. Lack of data during the COVID-19 pandemic strongly limits the possibility of tracing the real management of the disease, which is only conceivable from past evidence in normal conditions. The pandemic further stressed the importance of remote monitoring. However, the deployment of device and digital application used to increase screening of individuals and monitor progression of retinal disease needs to be easily accessible to general practitioners.Entities:
Mesh:
Year: 2020 PMID: 33123599 PMCID: PMC7584941 DOI: 10.1155/2020/9036847
Source DB: PubMed Journal: J Diabetes Res Impact factor: 4.011
Figure 1Telemedicine approaches for the screening or the diagnosis of diabetic retinopathy.
Telemedicine approaches for the screening or the diagnosis of diabetic retinopathy (DR).
| Country | Sample size | Approach | Sensitivity/specificity | Usefulness | Savings | |
|---|---|---|---|---|---|---|
| Bawankar et al. [ | India | 560 | Bosch nonmydriatic fundus camera | Sensitivity: 91.2%, specificity: 96.9% | Large compliance and accessibility to medical care in rural areas | Estimated decreased costs |
| Rajalakshmi et al. [ | India | 301 | Carl Zeiss fundus camera and “Fundus on Phone” (FOP) | Sensitivity: 92.7%, specificity: 98.4% (for STDR ➔ 87.9% and 94.9%) | Sleekness, easy portability, and wireless connectivity ➔ easily usable in nonhospital settings | Use of long-life LED illumination and lithium-ion battery in FOP reduces the operational cost of FOP |
| Liesenfeld et al. [ | Germany | 129 | Slit-lamp biomicroscopy | Median sensitivity = 85%, median specificity = 90% | New perspectives ➔ send images | Estimated decreased costs |
| Sasso et al. [ | Italy | 1461 | Horus Scope | Specificity = 100%, sensitivity = 94.3% | Eye-care services available to everyone at a sustainable cost | Estimated mean cost per patient €3.02 vs. €7.75 of traditional fundus oculus examination |
| Russo et al. [ | Italy | 120 | Smartphone ophthalmoscopy (D-Eye) | NPDR—specificity: 95%, sensitivity: 80% | Portability, affordability, and connectivity of a smartphone ophthalmoscope | Relatively low hardware and production costs (final retail price <$300) |
| Andonegui et al. [ | Spain | 1223 | Nonmydriatic retinal camera (TRC NW6S, Topcon, USA) | Specificity: 83%, sensitivity: 91%. | Cheaper, less time-consuming, easily applicable to populations far from the specialists, no requirement of pupil dilation | More cost-effective than traditional methods of DR screening |
| Gomez-Ulla et al. [ | Spain | — | Nonmydriatic fundus camera (Canon, Model CR5-45NM) | — | Larger accessibility | Reduced costs |